靶向 HIF-1 治疗急性髓细胞白血病。

IF 23.5 1区医学 Q1 ONCOLOGY

Nature cancer Pub Date : 2024-06-27 DOI:10.1038/s43018-024-00779-0

Darragh Flood, Cormac T. Taylor

引用次数: 0

摘要

急性髓性白血病（AML）是一种侵袭性血液肿瘤，治疗方案有限。现在的一项研究提供了令人信服的数据，并开发出一种用脯氨酰羟化酶抑制剂靶向治疗急性髓性白血病的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Targeting HIF-1 to treat AML

查看原文本刊更多论文

Targeting HIF-1 to treat AML

Acute myeloid leukemia (AML) is an aggressive hematological cancer with limited treatment options. A study now provides compelling data and develops a therapeutic approach of targeting AML with a prolyl hydroxylase inhibitor, a strategy based on the sensitivity of myeloid cells to modulation of the transcription factor HIF.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature cancer Medicine-Oncology

CiteScore

31.10

自引率

1.80%

发文量

129

期刊介绍： Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.